Search

Your search keyword '"Chen, Jo‐Pai"' showing total 39 results
Start Over Author "Chen, Jo‐Pai"
39 results on '"Chen, Jo‐Pai"'

1. Prognostic factors and risk-stratification model of recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen

Author

Yang, Muh-Hwa, Chen, Tien-Hua, Wang, Hung-Ming, Hsieh, Jason Chia-Hsun, Huang, Huai-Cheng, Hsieh, Meng-Che, Yen, Chia-Jui, Wu, Shang-Yin, Hua, Chun-Hung, Lien, Ming-Yu, Chang, Yi-Fang, Wang, Hui-Ching, Chien, Chih-Yen, Huang, Tai-Lin, Lu, Hsueh-Ju, Lin, Jin-Ching, Wang, Chen-Chi, Liu, Yi-Chun, Chen, Jo-Pai, Lu, Wei-Chen, Yiu, Ching-Yi, Lin, Chien-Liang, Lou, Pei-Jen, and Chu, Pen-Yuan

Published
2024
Full Text
View/download PDF

4. Increased Tuberculosis Reactivation Risk in Patients Receiving Immune Checkpoint Inhibitor-Based Therapy

Author

Chen, Hsing-Wu, primary, Kuo, Yao-Wen, additional, Chen, Chung-Yu, additional, Chang, Chin-Hao, additional, Wang, Su-Mei, additional, Chien, Ying-Chun, additional, Lu, Wei-Chen, additional, Chen, Jo-Pai, additional, Chang, Cheng-Yu, additional, Wei, Yu-Feng, additional, Chang, Shih-Chieh, additional, Shu, Chin-Chung, additional, Wang, Jann-Yuan, additional, Liao, Wei-Yu, additional, Wang, Hao-Chien, additional, and Yu, Chong-Jen, additional

Published
2024
Full Text
View/download PDF

6. Clinical outcomes of cetuximab‐based treatment for distant metastatic head and neck squamous cell carcinoma: A real‐world study using Taiwan Head Neck Society registry database.

Author

Lu, Hsueh‐Ju, Hsieh, Meng‐Che, Wang, Hung‐Ming, Hsieh, Jason Chia‐Hsun, Yen, Chia‐Jui, Wu, Shang‐Yin, Huang, Huai‐Cheng, Wang, Hui‐Ching, Chu, Pen‐Yuan, Chen, Tien‐Hua, Chien, Chih‐Yen, Huang, Tai‐Lin, Chang, Yi‐Fang, Hua, Chun‐Hung, Lien, Ming‐Yu, Chen, Jo‐Pai, Lu, Wei‐Chen, Lin, Jin‐Ching, Wang, Chen‐Chi, and Liu, Yi‐Chun

Subjects
SQUAMOUS cell carcinoma, HEAD & neck cancer, DATABASES, BETEL nut, TREATMENT effectiveness, OLDER patients
Abstract

Background: For R/M HNSCC, the differences in prognosis and treatment options between distant metastasis (DM) and locoregional recurrence, especially in the DM group, remain unclear. Methods: From the Taiwan Head Neck Society registry database, patients who were diagnosed with R/M HNSCC and received cetuximab‐based frontline therapy were collected for analysis. Results: Among the enrolled patients, 59.3% (491/827) belonged to the DM group. The DM group had less primary site of oral cavity, less betel nut chewing, higher lactate dehydrogenase (LDH) levels, and higher LDH/albumin ratio compared with the non‐DM group. For the patients with primary site of oral cavity and current smokers, DM coexisted with poorer outcomes. In the DM group, EXTREME‐like regimen was more suitable for older patients, those with elevated LDH, and those with higher LDH/albumin ratio than TPExtreme‐like regimen. Conclusion: DM coexisted with poorer prognosis in certain groups. LDH‐associated biomarkers may aid treatment options for DM patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. A real-world study of prognostic factors and risk-stratification model from Taiwanese patients with recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regimen.

Author

Yang, Muh-Hwa, primary, Tien Hua, Chen, additional, Hsieh, Meng-Che, additional, Huang, Huai-Cheng, additional, Chien, Chih-Yen, additional, Huang, Tai-Lin, additional, Hua, Chun-Hung, additional, Lien, Ming-Yu, additional, Wang, Hui-Ching, additional, Lu, Hsueh-Ju, additional, Yen, Chia-Jui, additional, Wu, Shang-Yin, additional, Chen, Jo-Pai, additional, Lu, Wei-Chen, additional, Lin, Jin-Ching, additional, Wang, Chen-Chi, additional, Liu, Yi-Chun, additional, Wang, Hung-Ming, additional, Heieh, Jason, Chia-Hsun, additional, and Lou, Pei-Jen, additional

Published
2022
Full Text
View/download PDF

23. Bleeding complications and possible resistance patterns of anti-angiogenesis treatments in recurrent/metastatic head-and-neck squamous cell carcinoma – Reflections from a phase II study of pazopanib in recurrent/metastatic head-and-neck squamous cell carcinoma

Author

Chen, Jo-Pai and Hong, Ruey-Long

Subjects
*HEMORRHAGE, *NEOVASCULARIZATION inhibitors, *THERAPEUTICS, *HEAD & neck cancer, *SQUAMOUS cell carcinoma, *CLINICAL trials
Abstract

Background: Due to smoking, alcohol, and betel nut use, head-and-neck squamous cell carcinoma (HNSCC) is a serious public health problem in Taiwan. Materials and Methods: We performed a single-arm Phase II trial of pazopanib in patients with platinum-refractory recurrent or metastatic HNSCC in 2011. Results: We screened 43 patients in about 6 months. Thirty-three of the patients were excluded due to easy bleeding and vessel contact resulting from the advanced tumor status. The remaining ten patients were included in this study. An objective response was seen in one patient; six patients had clinical benefits, which was comparable with the outcomes of sorafenib or sunitinib in this patient group. Four patients experienced at least Grade 3 bleeding. The tumor response was usually seen in the central cavity; the rim of the cavity extended outside, reflecting peripheral invasion and future resistance. Conclusion: The early use of anti-angiogenesis treatments is necessary for better tumor control and to prevent bleeding and potential resistance. In future, vascular endothelial growth factor receptor and/or epidermal growth factor receptor tyrosine kinase inhibitors may be used in combination with immunotherapy to increase the clinical benefits and avoid the risk of hyperprogression. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results